New treatment trends in viral hepatitis B+D
Keywords:
viral hepatitis B D, treatment, REP-2139-Ca, PegIFNAbstract
In the clinical study there were 12 patients with viral hepatitis B+D, aged between 18-55 years, of which 7 men and 5 women. The diagnosis was established based on anamnestic, clinical, biochemical, molecular biological, serological and imaging data. Combined treatment with nucleic acid polymers (REP 2139-Ca) and pegylated interferons was performed for 48 weeks with 1-year post-treatment follow-up. A functional cure expressed by anti-HBs seroconversion was found in 5 patients out of 12, VHD-RNA negativity in 8 patients out of 12, and HBV-DNA was undetectable in all patients and normalization of cytolysis syndrome indices at 1 year posttreatment follow-up.
References
1. Abbas M., Abbas Z. Serum cholinesterase: A predictive biomarker of hepatic reserves in chronic hepatitis D. In: World Journal of Hepatology. 2017, vol. 9, pp. 967-972. ISSN 1948- 5182. https://doi.org/10.4254/wjh.v9.i22.967
2. Anderson R. T., Choi H., Lenz O., Peters M. G., et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. In: Clinical Gastroenterology and Hepatology. 2021;19:463-72. https://doi.org/10.1016/j.cgh.2020.05.041
3. Bazinet M., Anderson M., Pântea V., Placinta G., et al. HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection. In: Hepatology communications. 2022, vol 6(8), p.1870-1880. Online ISSN:2471-254X. https://doi.org/10.1002/hep4.1951
4. Bazinet M., Pantea V., Cebotarescu V. et.al. Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results 187 from the REP 301-LTF study. In: Journal of Hepatology. 2018, vol. 68, nr. 1. ISSN 0168- 8278. https://doi.org/10.1016/S0168-8278(18)31266-2
5. Croagh C. et al. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. In: World Journal of Hepatology. 2015, vol. 7, nr. 3, pp. 289-292. ISSN 1948-5182. https://doi.org/10.4254/wjh.v7.i3.289
6. European Association for the Study of the Liver. Clinical Practice Guidelines on hepatitis delta virus. In: Journal of hepatology. 2023, vol. 79, p. 433-460 https://doi.org/10.1016/j.jhep.2023.05.001
7. Farci P, Anna Niro G. Current and Future Management of Chronic Hepatitis D. Gastroenterol Hepatol (N Y). 2018 Jun;14(6):342-351. PMID: 30166948; PMCID: PMC6111511. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111511/.
8. Kamili,S., Drobeniuc J., Mixson‐Hayden T., Kodani M. Delta hepatitis: toward improved diagnostics. In: Hepatology, 2017; 66:1716-18. https://doi.org/10.1002/hep.29564
9. Moucari R., Mackiewicz V., Lada O., Ripault M-P., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. In: Hepatology. 2009;49:1151-7. https://doi.org/10.1002/hep.22744
10. Rizzetto M. Hepatitis D. Virus: Introduction and Epidemiology. In: Cold Spring Harbor Perspectives in Medicine. 2015, nr. 5, pp. a021576. ISSN 2157-1422. https://doi.org/10.1101/cshperspect.a021576
11. Sureau C., Negro F. The hepatitis delta virus: replication and pathogenesis. In: Journal of Hepatology. 2016;64:S102-S116. https://doi.org/10.1016/j.jhep.2016.02.013
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
